PUBLICATION

Bioluminescent Zebrafish Transplantation Model for Drug Discovery

Authors
Hason, M., Jovicic, J., Vonkova, I., Bojic, M., Simon-Vermot, T., White, R.M., Bartunek, P.
ID
ZDB-PUB-220514-60
Date
2022
Source
Frontiers in pharmacology   13: 893655 (Journal)
Registered Authors
Bartunek, Petr, White, Richard M.
Keywords
bioluminescence, cancer, high-throughput screening, inhibitor, xenotransplantation, zebrafish
MeSH Terms
none
PubMed
35559262 Full text @ Front Pharmacol
Abstract
In the last decade, zebrafish have accompanied the mouse as a robust animal model for cancer research. The possibility of screening small-molecule inhibitors in a large number of zebrafish embryos makes this model particularly valuable. However, the dynamic visualization of fluorescently labeled tumor cells needs to be complemented by a more sensitive, easy, and rapid mode for evaluating tumor growth in vivo to enable high-throughput screening of clinically relevant drugs. In this study we proposed and validated a pre-clinical screening model for drug discovery by utilizing bioluminescence as our readout for the determination of transplanted cancer cell growth and inhibition in zebrafish embryos. For this purpose, we used NanoLuc luciferase, which ensured rapid cancer cell growth quantification in vivo with high sensitivity and low background when compared to conventional fluorescence measurements. This allowed us large-scale evaluation of in vivo drug responses of 180 kinase inhibitors in zebrafish. Our bioluminescent screening platform could facilitate identification of new small-molecules for targeted cancer therapy as well as for drug repurposing.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping